ENDOCYTE INC Contracts & Agreements
85 Contracts & Agreements
- Business Finance (11 contracts)
- Business Operations (32)
- Human Resources (15)
- Intellectual Property (9)
- Mergers & Acquisitions (1)
- Real Estate (15)
- Uncategorized (2)
- Form of Amendment to Change in Control and Severance Agreement (Filed With SEC on December 21, 2018)
- Agreement and Plan of Merger, dated as of October 17, 2018, by and among Novartis AG, Edinburgh Merger Corporation and Endocyte, Inc (Filed With SEC on October 18, 2018)
- Underwriting Agreement, dated as of September 11, 2018, by and among the Company and Jefferies LLC, Wells Fargo Securities, LLC, and RBC Capital Markets, LLC, as representatives... (Filed With SEC on September 12, 2018)
- Fifth Amendment to Office Lease dated May 29, 2018 between Endocyte, Inc. and Tempus One College Park LLC as successor in interest to Zeller Management Corporation (Filed With SEC on August 1, 2018)
- Second Amendment of Lease dated June 14, 2018 between Endocyte, Inc. and Purdue Research Foundation (Filed With SEC on August 1, 2018)
- Form of 2010 Equity Incentive Plan Time-Based Restricted Stock Unit Award Agreement (Employees) (for use after July 18, 2018) (Filed With SEC on August 1, 2018)
- Form of 2010 Equity Incentive Plan Stock Option Award Agreement (Employees) (for use after July 18, 2018) (Filed With SEC on August 1, 2018)
- Form of 2010 Equity Incentive Plan Time-Based Restricted Stock Unit Award Agreement (Directors Initial Grants) (for use after July 18, 2018) (Filed With SEC on August 1, 2018)
- Form of 2010 Equity Incentive Plan Stock Option Award Agreement (Directors Initial Grants) (for use after July 18, 2018) (Filed With SEC on August 1, 2018)
- Form of 2010 Equity Incentive Plan Time-Based Restricted Stock Unit Award Agreement (Directors Annual Grants) (for use after July 18, 2018) (Filed With SEC on August 1, 2018)
- Form of 2010 Equity Incentive Plan Stock Option Award Agreement (Directors Annual Grants) (for use after July 18, 2018) (Filed With SEC on August 1, 2018)
- Global Supply Agreement, dated as of July 5, 2018, between Endocyte, Inc. and ITG Isotope Technologies Garching GmbH (Filed With SEC on July 11, 2018)
- Fourth Amendment to Office Lease dated January 26, 2018 between Endocyte, Inc. and Tempus One College Park LLC as successor in interest to Zeller Management Corporation (Filed With SEC on May 9, 2018)
- Underwriting Agreement, dated as of February 28, 2018, by and among the Company and Jefferies LLC, Wells Fargo Securities, LLC, and Deutsche Bank Securities Inc., as... (Filed With SEC on February 28, 2018)
- Amendment #20 to the Amended and Restated Exclusive License Agreement dated October 21, 1998 between Endocyte, Inc. and Purdue Research Foundation, as amended (Filed With SEC on February 27, 2018)
- Amendment #3 to the Exclusive License Agreement effective March 1, 2010 between Endocyte, Inc. and Purdue Research Foundation, as amended (Filed With SEC on February 27, 2018)
- Amendments #9 and #10 to the Master License Agreement effective July 1, 2013 between Endocyte, Inc. and Purdue Research Foundation, as amended (Filed With SEC on February 27, 2018)
- First Amendment of lease dated November 10, 2017 between Endocyte, Inc. and Purdue Research Foundation (Filed With SEC on February 27, 2018)
- chedule of Terms for Change in Control and Severance Agreements with Executive Officers (Filed With SEC on February 27, 2018)
- Form of Warrant to Purchase Shares of Common Stock, dated as of September 29, 2017 (Filed With SEC on October 2, 2017)
- Registration Rights Agreement, dated as of September 29, 2017, between Endocyte, Inc. and ABX advanced biochemical compounds Biomedizinische Forschungsreagenzien GmbH (Filed With SEC on October 2, 2017)
- AMENDMENT #14 TO LICENSE AGREEMENT ID LA0003Endocyte Between Purdue Research Foundation and Endocyte Corporation (Filed With SEC on May 10, 2017)
- Second Amendment to the Amended and Restated License Agreement made effective on March 1, 2010 between the Purdue Research Foundation and Endocyte, Inc. (“Agreement”) (Filed With SEC on May 10, 2017)
- AMENDMENT #1 TO LICENSE AGREEMENT ID 2014-0052 Between Purdue Research Foundation and Endocyte, Inc. (Filed With SEC on May 10, 2017)
- PURDUE TECHNOLOGY CENTER 3000 Kent Avenue West Lafayette, Indiana 47906 EXTENSION OF LEASE (Filed With SEC on March 13, 2017)
- SEPARATION AGREEMENT AND RELEASE OF CLAIMS (Filed With SEC on March 13, 2017)
- ENDOCYTE, INC. SCHEDULE OF TERMS FOR CHANGE IN CONTROL AND SEVERANCE AGREEMENTS WITH EXECUTIVE OFFICERS March 2017 (Filed With SEC on March 13, 2017)
- SEPARATION AGREEMENT AND RELEASEOF CLAIMS (Filed With SEC on June 20, 2016)
- WARRANT TO PURCHASE SHARES OF COMMONSTOCK (Filed With SEC on March 8, 2016)
- PURDUE TECHNOLOGY CENTER 3000KENT AVENUE WESTLAFAYETTE, INDIANA 47906 LEASE AGREEMENT (Filed With SEC on March 8, 2016)
- ENDOCYTE, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT (Filed With SEC on May 18, 2015)
- MASTER LICENSE AGREEMENT Between PURDUE RESEARCH FOUNDATION and ENDOCYTE, INC. TABLE OF CONTENTS (Filed With SEC on March 13, 2015)
- SEPARATION AGREEMENT AND RELEASEOF CLAIMS (Filed With SEC on November 7, 2014)
- FOURTH AMENDMENT OF LEASE AGREEMENT (Filed With SEC on August 8, 2014)
- LICENSE AGREEMENT BETWEEN ENDOCYTE, INC AND PURDUE RESEARCH FOUNDATION OCTOBER 21, 1998 (Filed With SEC on August 8, 2014)
- EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on August 8, 2014)
- THIRD AMENDMENT OF LEASE AGREEMENT (Filed With SEC on May 12, 2014)
- 4,500,000 Shares ENDOCYTE, INC. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on March 31, 2014)
- PURDUE TECHNOLOGY CENTER 3000kent avenue westlafayette, indiana 47906 EXTENSION OF LEASE (Filed With SEC on March 5, 2014)
- ENDOCYTE, INC. 2010 EQUITY INCENTIVE PLAN TIME-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT (Filed With SEC on February 10, 2014)
- Endocyte,Inc. $60,000,000 COMMON STOCK SALES AGREEMENT (Filed With SEC on December 23, 2013)
- SECOND AMENDMENT OF LEASE AGREEMENT (Filed With SEC on November 8, 2013)
- WARRANT TO PURCHASE SHARES OF COMMON STOCK OF ENDOCYTE, INC. (Filed With SEC on August 9, 2013)
- FIRST AMENDMENT OF LEASE AGREEMENT (Filed With SEC on August 9, 2013)
- THIRDAMENDMENT TO OFFICE LEASE (Filed With SEC on March 18, 2013)
- PURDUE TECHNOLOGY CENTER 3000kent avenue westlafayette, indiana 47906 LEASE AGREEMENT (Filed With SEC on March 18, 2013)
- COLLABORATION, EXCLUSIVE LICENSE, AND COMPANION DIAGNOSTIC AGREEMENT by and between Merck Sharp & Dohme Research GmbHand ENDOCYTE, INC. (Filed With SEC on August 13, 2012)
- Lease Agreement (Filed With SEC on March 28, 2012)
- PURDUE TECHNOLOGY CENTER 3000 KENT AVENUE WEST LAFAYETTE, IN 47906 EXTENSION OF LEASE (Filed With SEC on March 28, 2012)
- THIRD LOAN MODIFICATION AGREEMENT (Filed With SEC on November 14, 2011)
- [ ] Shares Endocyte, Inc. Common Stock ($0.001 Par Value) UNDERWRITING AGREEMENT (Filed With SEC on July 21, 2011)
- SECOND LOAN MODIFICATION AGREEMENT (Filed With SEC on July 21, 2011)
- ENDOCYTE, INC. 2010 EQUITY INCENTIVE PLAN PERFORMANCE-BASED RESTRICTED STOCK UNIT AWARD AGREEMENT (2011 RSU PROGRAM) (Filed With SEC on June 2, 2011)
- Current assets (Filed With SEC on May 13, 2011)
- Current assets (Filed With SEC on May 13, 2011)
- Obtain marketing approval of our phase 3-ready SMDC, EC145, for use in women with platinum-resistant ovarian cancer. We plan to initiate a randomized, controlled, double-blinded... (Filed With SEC on March 18, 2011)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on January 12, 2011)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on January 12, 2011)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on December 15, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on December 15, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on December 15, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on December 15, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on September 28, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on September 28, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on September 28, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on September 28, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on September 28, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on September 28, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on September 28, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on September 28, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on September 28, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on September 28, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on September 28, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on September 28, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on August 17, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on August 17, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on August 17, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on August 17, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on August 17, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on August 17, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on August 17, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on August 17, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on August 17, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on August 17, 2010)
- obtain marketing approval of our phase 3-ready SMDC, EC145, for treatment of women with platinum-resistant ovarian cancer (Filed With SEC on August 17, 2010)
